



09-03-02

GAU 1646

CASE OP/4-31881A

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EL 820010560 US

Express Mail Label Number

8/30/02

Date of Deposit

#7  
9-10-02  
P.2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

**RECEIVED**

SEP 05 2002

IN RE APPLICATION OF

Art Unit: 1646

BRAZZELL ET AL.

TECH CENTER 1600/2900

APPLICATION NO: 10/080,797

FILED: FEBRUARY 21, 2002

FOR: METHOD OF TREATING OCULAR NEOVASCULARIZATION

Assistant Commissioner for Patents  
Washington, D.C. 20231

INFORMATION DISCLOSURE STATEMENT

Sir:


Applicants believe this paper is being filed before the mailing date of a first Office Action on the merits, and so under 37 C.F.R. §1.97(b)(3) no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.

Copies of these references are enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Respectfully submitted,

A handwritten signature in cursive script, reading "David E. Wildman", written over a horizontal line.

David E. Wildman  
Attorney for Applicants  
Reg. No. 40,226

Novartis Corporation  
Patent and Trademark Dept.  
564 Morris Avenue  
Summit, NJ 07901-1027  
(908) 522-6946

Date: 8/30/02